Form D · Pharmaceuticals
Revere Pharmaceuticals Inc.
Arlington, MA · CIK 0001778959
Offering snapshot reported Jun 12, 2023 · SEC filing
- Reported sold
- $1.62M Offering amount: $3.56M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 1, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 12, 2023 | Initial | $1,622,604 | No comparison | 22 | SEC filing |
| Sep 1, 2021 | Initial | $1,056,199 | No comparison | 30 | SEC filing |
| Jan 12, 2021 | Amendment | $3,454,842 | $1,867,479vs Jun 22, 2020 | 61 | SEC filing |
| Jun 22, 2020 | Amendment | $1,587,363 | $374,989vs Jun 21, 2019 | 30 | SEC filing |
| Jun 21, 2019 | Initial | $1,212,374 | No comparison | 20 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-483952
Source: Form D, filed Jun 12, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jedd Levine | Director, Executive |
| Marc Lippman | Director |
| Kollol Pal | Director |
| Ian Robert Silverman | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
36 Orvis Road
Arlington, MA, 02474
Arlington, MA, 02474